Morgan H. James

Dr. Morgan H. James

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2014 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
SMStephen Mahler
Stephen Mahler
DMDavid E Moorman
David E Moorman
RSRachel J Smith
Rachel J Smith
MJMorgan H. James
Morgan H. James
GAGary Aston-Jones
Gary Aston-Jones

1 December 2015 in Brain Research
Verified
Journal Article
Closed access
DMDavid E. Moorman
David E. Moorman
MJMorgan H. James
Morgan H. James
EMEllen M. McGlinchey
Ellen M. McGlinchey
GAGary Aston-Jones
Gary Aston-Jones

1 June 2019 in Biological Psychiatry
Verified
Journal Article
Closed access
MJMorgan H. James
Morgan H. James
CSColin M. Stopper
Colin M. Stopper
BZBenjamin A. Zimmer
Benjamin A. Zimmer
NKNikki E. Koll
Nikki E. Koll
HBHannah E. Bowrey
Hannah E. Bowrey
GAGary Aston-Jones
Gary Aston-Jones

24 December 2016
Verified
Book Chapter
Open access
PDF file
MJMorgan H. James
Morgan H. James
SMStephen Mahler
Stephen Mahler
DMDavid E. Moorman
David E. Moorman
GAGary Aston-Jones
Gary Aston-Jones
One decade ago, our laboratory provided the first direct evidence linking orexin/hypocretin signaling with drug seeking by showing that activation of these neurons promotes conditioned morphine-seeking behavior. In the years since, contributions from many investigators have revealed roles for orexins in addiction for all drugs of abuse tested, but only under select circumstances. We recently proposed that orexins play a fundamentally unified role in coordinating “motivational activation” under numerous behavioral conditions, and here we unpack this hypothesis as it applies to drug addiction. We describe evidence collected over the past 10 years that elaborates the role of orexin in drug seeking under circumstances where high levels of effort are required to obtain the drug, or when motivation for drug reward is augmented by the presence of external stimuli like drug-associated cues/contexts or stressors. Evidence from studies using traditional self-administration and reinstatement models, as well as behavioral economic analyses of drug demand elasticity, clearly delineates a role for orexin in modulating motivational, rather than the primary reinforcing aspects of drug reward. We also discuss the anatomical interconnectedness of the orexin system with wider motivation and reward circuits, with a particular focus on how orexin modulates prefrontal and other glutamatergic inputs onto ventral tegmental area dopamine neurons. Last, we look ahead to the next decade of the research in this area, highlighting the recent FDA approval of the dual orexin receptor antagonist suvorexant (Belsomra®) for the treatment of insomnia as a promising sign of the potential clinical utility of orexin-based therapies for the treatment of addiction.

17 August 2016 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EMEllen M. McGlinchey
Ellen M. McGlinchey
MJMorgan H. James
Morgan H. James
SMStephen Mahler
Stephen Mahler
CPCaroline Pantazis
Caroline Pantazis
GAGary Aston-Jones
Gary Aston-Jones
Glutamate inputs to nucleus accumbens (NAc) facilitate conditioned drug-seeking behavior and primarily originate from medial prefrontal cortex (mPFC), basolateral amygdala (BLA), and ventral subiculum of the hippocampus (vSub). These regions express Fos (a marker of neural activity) during cue-induced reinstatement of cocaine seeking, but only subpopulations of neurons within these regions drive drug seeking. One way to identify and functionally distinguish neural subpopulations activated during drug-seeking is to examine their projection targets. In rats, we examined Fos expression during cue-induced reinstatement of cocaine- and sucrose-seeking in prelimbic cortex (PL), infralimbic cortex (IL), BLA, and vSub neurons that project to NAc core (NAcC) or NAc shell (NAcSh). Neurons in PL, BLA, and vSub that project to NAcC, but not NAcSh, expressed Fos during cue-induced cocaine seeking, but not sucrose seeking. However, only activation of the PL-NAcC pathway positively correlated with cocaine reinstatement behavior, unlike BLA or vSub inputs to NAcC. To confirm a functional role for the PL-NAcC pathway, and to test the hypothesis that this pathway is recruited in a dopamine-dependent manner, we used a pharmacological disconnection approach whereby dopamine signaling was blocked in PL and glutamate signaling was blocked in the contralateral NAcC. This disconnection attenuated cue-induced reinstatement of cocaine seeking but had no effect on reinstatement of sucrose seeking. Our results highlight a role for the PL-NAcC pathway in cocaine seeking and show that these glutamatergic projections are recruited in a dopamine-dependent manner to drive reinstatement. SIGNIFICANCE STATEMENT Relapse represents a significant barrier to the successful treatment of cocaine addiction. Here, we characterize the relative activation of glutamatergic inputs to nucleus accumbens during cued reinstatement of cocaine seeking versus sucrose seeking. Prelimbic cortex (PL) projections to nucleus accumbens core (NAcC) uniquely expressed Fos in a manner that positively correlated with cocaine-seeking, but not sucrose-seeking, behavior. Additional functional experiments showed that the PL-NAcC pathway was recruited by drug-associated cues in a dopamine-dependent manner to drive cocaine-seeking, but not sucrose-seeking, behavior. These data highlight PL neurons that project to NAcC, and their regulation by dopamine, as potential targets for therapeutics designed to treat cocaine relapse that do not affect natural reward seeking.

1 June 2011 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MJMorgan H. James
Morgan H. James
JCJanine L. Charnley
Janine L. Charnley
ELEmily M. Levi
Emily M. Levi
EJEmma Jones
Emma Jones
JYJiann Wei Yeoh
Jiann Wei Yeoh
CDChristopher V. Dayas
Christopher V. Dayas
Orexinergic signalling is critical to drug relapse-like behaviour; however, the CNS sites(s) of action remain unknown. Two candidate brain regions are